NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Correct. But BioHarm needs everyone to think it is approved.

>>The FDA (the U.S. Food and Drug Administration) has not approved personalized neoantigen
peptides, Hiltonol® or Montanide® a as a treatment for any disease.

>>The FDA (the U.S. Food and Drug Administration) has not approved personalized neoantigen
peptides, Hiltonol® or Montanide® a as a treatment for any disease. It is an investigational
drug being developed for use in the treatment of metastatic melanoma.

The FDA has approved Nivolumab (Opdivo®) and Ipilimumab (Yervoy™) as a treatment option for
this disease.

The FDA has approved Ipilimumab administered intravenously as a treatment option for this
disease.

The FDA has not approved Ipilimumab administered subcutaneously (under the skin) as a
treatment for any disease.

https://www.mycancergenome.org/content/clinical_trials/NCT03929029/


>>The drug was also under development for the treatment of brain tumor, anaplastic astrocytoma, anaplastic oligoastrocytoma, oligodendroglioma, glioblastoma multiforme, poxviridae infections, west nile virus infections, japanese encephalitis, dengue fever, yellow fever, st louis encephalitis, murray valley, orthopox virus infections, banzai viruses, smallpox, severe acute respiratory syndrome (SARS), acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and influenza.

The company’s pipeline products include hiltonol plus dendritic cell vaccine and hiltonol (Poly-ICLC) plus temodar.

https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/?cf-view